<DOC>
	<DOCNO>NCT03030300</DOCNO>
	<brief_summary>To evaluate long-term remission rate short-term intensive insulin ( STII ) therapy newly diagnose type 2 diabetes outpatient investigate predictor contribute remission rate .</brief_summary>
	<brief_title>Remission Rate Newly Diagnosed Type 2 Diabetes Outpatients Treated With Short-term Intensive Insulin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Newly diagnose , insulinnaive type 2 diabetes outpatient Diabetes duration less 1 year Various acute complication Hepatic transaminase &gt; 2.5x normal reference value ( glutamicpyruvic transminase &gt; 100U/L , glutamicoxalacetic transaminase &gt; 100U/L ) Abnormal renal function ( serum cretinine &gt; normal reference value ) Cardiac insufficiency ( America NYHA caediac function &gt; 3 ) Type 1 diabetes mellitus Ongoing hormone therapy Women gestation lactation Patients endocrine disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>remission</keyword>
	<keyword>short-term intensive insulin therapy</keyword>
</DOC>